Targeting CD123 via CAR-engineered T cells, neutralizing antibodies, and IL3RA antibodies coupled to toxins has been shown to have beneficial effects on the survival of AML models [38–41]. The gene discussed is IL3RA; the disease is acute myeloid leukemia.